Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Vassallo, R.; Ryu, J.H.; Schroeder, D.R.; Decker, P.A.; Limper, A.H. Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults. N. Engl. J. Med. 2002, 346, 484–490. [Google Scholar] [CrossRef] [PubMed]
- Kaya, A.; Savaş, Y.; Sen, E.; Sak, S.D.; Güngör, A.; Gönüllü, U. Histiocytosis X and bronchopulmonary adenocarcinoma: A rare coexistence. Can. Respir. J. 2002, 9, 431–432. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Howarth, D.M.; Gilchrist, G.S.; Mullan, B.P.; Wiseman, G.A.; Edmonson, J.H.; Schomberg, P.J. Langerhans cell histiocytosis: Diagnosis, natural history, management, and outcome. Cancer 1999, 85, 2278–2290. [Google Scholar] [CrossRef]
- Lombard, C.M.; Medeiros, L.J.; Colby, T.V. Pulmonary histiocytosis X and carcinoma. Arch. Pathol. Lab Med. 1987, 111, 339–341. [Google Scholar] [PubMed]
- Sadoun, D.; Vaylet, F.; Valeyre, D.; Natali, F.; Georges, R.; Allard, P.; Battesti, J.P. Bronchogenic carcinoma in patients with pulmonary histiocytosis X. Chest 1992, 101, 1610–1613. [Google Scholar] [CrossRef][Green Version]
- Khaliq, M.F.; Noorani, M.M.; Tariq, S.M.; Koirala, A.; Mohamed, H. Pulmonary Langerhans Cell Histiocytosis Associated with Bronchogenic Carcinoma. Cureus 2020, 12, e6634. [Google Scholar] [CrossRef] [PubMed]
- Ohtsuki, Y.; Uomoto, M.; Hashisuka, Y.; Kato, M.; Iguchi, M.; Lee, G.H.; Furihata, M. A rare case of coexistence of pulmonary adenocarcinoma with Langerhans’ cell histiocytosis. Med. Mol. Morphol. 2008, 41, 175–178. [Google Scholar] [CrossRef]
- Uskul, B.T.; Turker, H.; Bayraktar, O.U.; Onemli, M. Bronchogenic carcinoma developing during a long-term course of pulmonary Langerhans’ cell histiocytosis. Intern. Med. 2009, 48, 359–362. [Google Scholar] [CrossRef]
- Kalchiem-Dekel, O.; Paulk, A.; Kligerman, S.J.; Burke, A.P.; Shah, N.G.; Dixon, R.K. Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung. J. Thorac. Dis. 2017, 9, E1079–E1083. [Google Scholar] [CrossRef]
- Alden, S.L.; Swanson, S.J.; Nishino, M.; Sholl, L.M.; Awad, M.M. BRAF-Mutant pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma. JTO Clin. Res. Rep. 2020, 2, 100127. [Google Scholar] [CrossRef]
- Bhardwaj, H.; Bhardwaj, B.; Levin, D. Pulmonary adenocarcinoma in a young patient of pulmonary langerhans cell histiocytosis (PLCH). J. Thorac. Oncol. 2013, 8, e69–e70. [Google Scholar] [CrossRef] [PubMed]
- von der Thüsen, J.H.; van de Wetering, M.D.; Westermann, A.M.; Heideman, D.A.M.; Thunnissen, E. Bronchioloalveolar adenocarcinoma and pulmonary langerhans cell histiocytosis in a patient with MUTYH-associated polyposis. J. Clin. Oncol. 2011, 29, e188–e190. [Google Scholar] [CrossRef] [PubMed]
- Gencer, A.; Ozcibik, G.; Karakas, F.G.; Sarbay, I.; Batur, S.; Borekci, S.; Turna, A. Two smoking-related lesions in the same pulmonary lobe of squamous cell carcinoma and pulmonary Langerhans cell histiocytosis: A case report. World J. Clin. Cases 2022, 10, 6722–6727. [Google Scholar] [CrossRef] [PubMed]
- Sauter, J.L.; Dacic, S.; Galateau-Salle, F.; Attanoos, R.L.; Butnor, K.J.; Churg, A.; Husain, A.N.; Kadota, K.; Khoor, A.; Nicholson, A.G.; et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J. Thorac. Oncol. 2022, 17, 608–622. [Google Scholar] [CrossRef] [PubMed]
- Shaw, B.; Borchers, M.; Zander, D.; Gupta, N. Pulmonary Langerhans Cell Histiocytosis. Semin. Respir. Crit. Care Med. 2020, 41, 269–279. [Google Scholar] [CrossRef]
- Liu, H.; Osterburg, A.R.; Flury, J.; Swank, Z.; McGraw, D.W.; Gupta, N.; Wikenheiser-Brokamp, K.A.; Kumar, A.; Tazi, A.; Inoue, Y.; et al. MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. JCI Insight 2020, 5, e132048. [Google Scholar] [CrossRef]
- Kobayashi, M.; Tojo, A. The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis. Blood 2014, 124, 2610–2611. [Google Scholar] [CrossRef][Green Version]
- Zhang, L.; Pacheco-Rodriguez, G.; Seatgall, W.K.; Kato, J.; Colby, T.V.; Haughey, M.; Moss, J. BRAF and NRAS mutations in circulating Langerhans-like CD1a + cells in a patient with pulmonary Langerhans’ cell histiocytosis. Eur. Respir. J. 2017, 50, 1700521. [Google Scholar] [CrossRef]
- Héritier, S.; Hélias-Rodzewicz, Z.; Lapillonne, H.; Terrones, N.; Garrigou, S.; Normand, C. Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis. Br. J. Haematol. 2017, 178, 457–467. [Google Scholar] [CrossRef]
- Jouenne, F.; Chevret, S.; Bugnet, E.; Clappier, E.; Lorillon, G.; Meignin, V.; Sadoux, A.; Cohen, S.; Haziot, A.; How-Kit, A.; et al. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. Eur. Respir. J. 2020, 55, 1901190. [Google Scholar] [CrossRef]
- Mourah, S.; How-Kit, A.; Meignin, V.; Gossot, D.; Lorillon, G.; Bugnet, E.; Mauger, F.; Lebbe, C.; Chevret, S.; Tost, J.; et al. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur. Respir. J. 2016, 47, 1785–1796. [Google Scholar] [CrossRef] [PubMed]
- Ou, S.I.; Nagasaka, M.; Zhu, V.W. Liquid Biopsy to Identify Actionable Genomic Alterations. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 978–997. [Google Scholar] [CrossRef] [PubMed]
- Yousem, S.A.; Dacic, S.; Nikiforov, Y.E.; Nikiforova, M. Pulmonary Langerhans cell histiocytosis: Profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest 2013, 143, 1679–1684. [Google Scholar] [CrossRef] [PubMed]
- Kamionek, M.; Ahmadi Moghaddam, P.; Sakhdari, A.; Kovach, A.E.; Welch, M.; Meng, X.; Dresser, K.; Tomaszewicz, K.; Cosar, E.F.; Mark, E.J.; et al. Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease. Histopathology 2016, 69, 499–509. [Google Scholar] [CrossRef]
- Roden, A.C.; Hu, X.; Kip, S.; Parrilla Castellar, E.R.; Rumilla, K.M.; Vrana, J.A.; Vassallo, R.; Ryu, J.H.; Yi, E.S. BRAF V600E expression in Langerhans cell histiocytosis: Clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am. J. Surg. Pathol. 2014, 38, 548–551. [Google Scholar] [CrossRef]
- Paik, P.K.; Arcila, M.E.; Fara, M.; Sima, C.S.; Miller, V.A.; Kris, M.G.; Ladanyi, M.; Riely, G.J. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol. 2011, 29, 2046–2051. [Google Scholar] [CrossRef]
- Anglesio, M.S.; Papadopoulos, N.; Ayhan, A.; Nazeran, T.M.; Noë, M.; Horlings, H.M.; Lum, A.; Jones, S.; Senz, J.; Seckin, T.; et al. Cancer-Associated Mutations in Endometriosis without Cancer. N. Engl. J. Med. 2017, 376, 1835–1848. [Google Scholar] [CrossRef]
- Vallvé-Juanico, J.; López-Gil, C.; Ballesteros, A.; Santamaria, X. Endometrial Stromal Cells Circulate in the Bloodstream of Women with Endometriosis: A Pilot Study. Int. J. Mol. Sci. 2019, 20, 3740. [Google Scholar] [CrossRef]
- Hu, Y.; Ulrich, B.C.; Supplee, J.; Kuang, Y.; Lizotte, P.H.; Feeney, N.B.; Guibert, N.M.; Awad, M.M.; Wong, K.K.; Jänne, P.A.; et al. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin. Cancer Res. 2018, 24, 4437–4443. [Google Scholar] [CrossRef]
- Croitoru, V.M.; Cazacu, I.M.; Popescu, I.; Paul, D.; Dima, S.O.; Croitoru, A.E.; Tanase, A.D. Clonal Hematopoiesis and Liquid Biopsy in Gastrointestinal Cancers. Front. Med. 2022, 8, 772166. [Google Scholar] [CrossRef]
- Chan, H.T.; Chin, Y.M.; Nakamura, Y.; Low, S.K. Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Cancers 2020, 12, 2277. [Google Scholar] [CrossRef] [PubMed]
Reference | Gender | Age | Smoke | Tumor Stage | Genetic Alterations in Lung Cancer | Genetic Alterations in PLCH | Therapy | Outcome |
---|---|---|---|---|---|---|---|---|
Alden et al. | Female | 45 | Current | IIIB | KRAS (p.G12D) | BRAF (p.V600E) | Neoadjuvant chemotherapy; surgery | Alive (>6 months) |
Kalchiem-Dekel et al. | Female | 56 | Current | IV | BRAF (p. V600E) | None | Chemotherapy + radiotherapy | Lost to follow-up |
Our case | Male | 35 | Current | IIB | KRAS (p. G12C) | BRAF (p.V600E) | Surgery; adjuvant chemotherapy | Died of disease (11 months) |
Our case | Male | 75 | Current | IB | KRAS (p.G13C) | None | Surgery; chemotherapy | Died of disease (35 months) |
Our case | Male | 72 | Current | IV | None | None | Chemotherapy | Died of disease (8 months) |
Khaliq et al. | Female | 76 | Current | IIA | N.A. | N.A. | Surgery | N.A. |
Von der Thusen et al. | Male | 14 | Never | IV | KRAS (p. G12C) | N.A. | Chemotherapy | N.A. (colonic carcinoma with MUTYH-associated polyposis) |
Bhardwaj et al. | Female | 28 | Current | IV | None (tested for EGFR and ALK only) | N.A. | Chemotherapy (cisplatin + pemetrexed) | N.A. |
Kaya et al. | Female | 28 | Current | IIA | N.A. | N.A. | Surgery | N.A. |
Ohtsuki et al. | Female | 78 | Never | IB | N.A. | N.A. | Surgery | N.A. |
Gancer et al. | Male | 70 | Current | IA | N.A. (squamous cell carcinoma) | BRAF (p.V600E) | Surgery | Alive (6 months) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Melocchi, L.; Mondoni, M.; Malapelle, U.; Rossi, G. Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations. J. Mol. Pathol. 2022, 3, 286-292. https://doi.org/10.3390/jmp3040024
Melocchi L, Mondoni M, Malapelle U, Rossi G. Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations. Journal of Molecular Pathology. 2022; 3(4):286-292. https://doi.org/10.3390/jmp3040024
Chicago/Turabian StyleMelocchi, Laura, Michele Mondoni, Umberto Malapelle, and Giulio Rossi. 2022. "Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations" Journal of Molecular Pathology 3, no. 4: 286-292. https://doi.org/10.3390/jmp3040024
APA StyleMelocchi, L., Mondoni, M., Malapelle, U., & Rossi, G. (2022). Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations. Journal of Molecular Pathology, 3(4), 286-292. https://doi.org/10.3390/jmp3040024